title: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
abstract: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative, established by the National Office of Public Health Genomics at the Centers for Disease Control and Prevention, supports the development and implementation of a rigorous, evidence-based process for evaluating genetic tests and other genomic applications for clinical and public health practice in the United States. An independent, non-federal EGAPP Working Group (EWG), a multidisciplinary expert panel selects topics, oversees the systematic review of evidence, and makes recommendations based on that evidence. This article describes the EGAPP processes and details the specific methods and approaches used by the EWG.
authors.affiliation: Merck & Company, Inc., West Point, Pennsylvania, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Teutsch
authors.forename: Linda A
authors.initials: LA
authors.lastname: Bradley
authors.forename: Glenn E
authors.initials: GE
authors.lastname: Palomaki
authors.forename: James E
authors.initials: JE
authors.lastname: Haddow
authors.forename: Margaret
authors.initials: M
authors.lastname: Piper
authors.forename: Ned
authors.initials: N
authors.lastname: Calonge
authors.forename: W David
authors.initials: WD
authors.lastname: Dotson
authors.forename: Michael P
authors.initials: MP
authors.lastname: Douglas
authors.forename: Alfred O
authors.initials: AO
authors.lastname: Berg
mesh_terms: D002487:Centers for Disease Control and Prevention, U.S.; D005069:Evaluation Studies as Topic; D019317:Evidence-Based Medicine / Q000379:methods*; D005821:Genetic Techniques / Q000592:standards; D005826:Genetics, Medical / Q000379:methods* / Q000639:trends; D023281:Genomics / Q000379:methods*; D006801:Humans; D014481:United States